Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA methyltransferase refers to a group of enzymes that mediate methyl group addition to RNA molecules, mainly using S-adenosyl-L-methionine (SAM) as a methyl donor. These enzymes recognize specific RNA substrates (e.g., mRNA, tRNA, rRNA), modifying nucleotides at distinct positions such as N6-adenosine (m^6A), 2’-O-ribose, or m^7G cap structures. Well-characterized families include METTL (Methyltransferase-like proteins, e.g., METTL3, METTL16), NSUN (NOP2/Sun), and TRMT (tRNA methyltransferase subfamilies). RNA methyltransferases are essential for epigenetic gene regulation, cell differentiation, RNA stability, and have been implicated in diverse pathologies including cancers and viral infections. Inhibitors of RNA methyltransferases are being investigated for therapeutic use, though clinical candidates are still emerging.
Inhibition of methyl group transfer to RNA nucleotides (reducing mRNA/tRNA modification) Modulation of RNA stability and translation Suppression of viral replication (by targeting viral MTases)
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA methyltransferase.